Back to Journals » Medical Devices: Evidence and Research » Volume 6
New treatment of iliac artery disease: focus on the Absolute Pro® Vascular Self-Expanding Stent System
Received 26 March 2013
Accepted for publication 21 May 2013
Published 13 September 2013 Volume 2013:6 Pages 147—150
DOI https://doi.org/10.2147/MDER.S31696
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Lindsay Gates, Jeffrey Indes
Vascular and Endovascular Surgery, Yale University School of Medicine, New Haven, CT, USA
Abstract: Management of iliac artery disease has evolved over the years, from a surgical-only approach to a primarily endovascular-only approach as the first line treatment option. This has been continuously improved upon with the advent of new devices and applied technologies. Most recently in particular, the literature has shown good, reliable outcomes with the use of self-expandable stents in iliac artery atherosclerotic lesions. Nevertheless, no device is without its limitations, and the Absolute Pro® Vascular Self-Expanding Stent System was designed with the intent of overcoming some of the shortcomings of other available stents while maintaining acceptable postprocedural outcomes. Based on preliminary industry-acquired data, it has achieved these goals and appears to be an emergent competitor for the treatment of both focal and complex iliac artery lesions.
Keywords: Absolute-Pro®, iliac stent, self-expanding stents, atherosclerotic disease
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.